Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials.
Gilles ManceauFernando RiveraSalvatore SienaMeinolf KarthausManuel Valladares-AyerbesJavier GallegoMichael GeisslerReija KoukakisGaston DemontyMarc PeetersPublished in: Journal of cancer research and clinical oncology (2017)
These exploratory analyses suggest that panitumumab is associated ETS and DpR benefits in patients with RAS WT mCRC and that achieving these endpoints during first-line treatment is linked with favourable outcomes.